Trans Genic Inc. Stock

Equities

2342

JP3635720000

Department Stores

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
248 JPY -5.70% Intraday chart for Trans Genic Inc. +9.25% -4.62%
Sales 2022 12.58B 79.73M Sales 2023 11.43B 72.46M Capitalization 5.6B 35.48M
Net income 2022 1.88B 11.89M Net income 2023 -409M -2.59M EV / Sales 2022 0.35 x
Net cash position 2022 2.8B 17.78M Net cash position 2023 1.04B 6.61M EV / Sales 2023 0.4 x
P/E ratio 2022
3.89 x
P/E ratio 2023
-13.7 x
Employees 236
Yield 2022
0.71%
Yield 2023
0.9%
Free-Float 92.66%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on November 22, 2023. CI
Trans Genic Inc.'s Equity Buyback announced on November 22, 2023, has closed with 300,000 shares, representing 1.78% for ¥78.62 million. CI
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on November 22, 2023. CI
Trans Genic Inc. announces an Equity Buyback for 300,000 shares, representing 1.78% for ¥100 million. CI
Trans Genic Inc. authorizes a Buyback Plan. CI
Trans Genic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Trans Genic Inc. acquired MASC Co., Ltd. CI
Eurofins Clinical Testing Lux Holding Sarl entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. for ¥3.2 billion. CI
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on August 25, 2021. CI
Trans Genic Inc.'s Equity Buyback announced on August 25, 2021, has closed with 550,000 shares, representing 3.19% for ¥298.6 million. CI
Trans Genic Inc. completed the acquisition of Lunapas LLC. CI
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on August 25, 2021. CI
Trans Genic Inc. entered into share transfer agreement to acquire Lunapas LLC. CI
Trans Genic Inc. announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million. CI
Trans Genic Inc. authorizes a Buyback Plan. CI
More news
1 day-5.70%
1 week+9.25%
Current month+2.90%
3 months-7.46%
6 months-9.16%
Current year-4.62%
More quotes
1 week
223.00
Extreme 223
271.00
1 month
222.00
Extreme 222
271.00
Current year
222.00
Extreme 222
271.00
1 year
222.00
Extreme 222
315.00
3 years
222.00
Extreme 222
655.00
5 years
222.00
Extreme 222
828.00
10 years
222.00
Extreme 222
1 404.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 09-05-31
Director of Finance/CFO 56 17-06-30
Director/Board Member 64 11-08-31
Members of the board TitleAgeSince
Director/Board Member 79 11-05-31
Chief Executive Officer 54 09-05-31
Director/Board Member 50 02-10-31
More insiders
Date Price Change Volume
24-04-26 248 -5.70% 274 100
24-04-25 263 +16.89% 1,513,600
24-04-24 225 0.00% 8,100
24-04-23 225 0.00% 13,300
24-04-22 225 0.00% 15,500

Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT

More quotes
TRANS GENIC INC. is a Japan-based company mainly engaged in the biotechnology business. The Company has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.
Calendar
More about the company